Payment overview · 2025
General Payments
$230.10
11 reported records · 6 companies
Healthcare provider profile · identity verified
James A Upshaw, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MACON, GA · NPI 1740252170
Verified facts
What the public records show
CMS Open Payments records show James A Upshaw, M.D. received $230.10 in general payments during 2025 across 11 reported records.
Amgen Inc. accounted for 26.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Shingrix.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 217 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Shingrix by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $61.21 | 26.6% | 4 | 2025 |
| McKesson Medical-Surgical, Inc. | Unresolved — no canonical attribution shown | $57.85 | 25.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $44.79 | 19.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $27.83 | 12.1% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $22.03 | 9.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.39 | 7.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $230.10 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $61.21 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $46.09 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $44.79 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $27.83 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $22.03 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.39 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 217 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 25 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
217 | 51 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
25 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
84 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 724 | 196 |
| Amlodipine Besylate | Amlodipine Besylate | 698 | 194 |
| Levothyroxine Sodium | Levothyroxine Sodium | 476 | 114 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 392 | 107 |
| Metoprolol Succinate | Metoprolol Succinate | 388 | 107 |
| Pantoprazole Sodium | Pantoprazole Sodium | 324 | 93 |
| Losartan Potassium | Losartan Potassium | 304 | 92 |
| Omeprazole | Omeprazole | 289 | 77 |
| Lisinopril | Lisinopril | 255 | 67 |
| Hydrochlorothiazide | Hydrochlorothiazide | 245 | 79 |
| Alprazolam | Alprazolam | 221 | 54 |
| Eliquis | Apixaban | 217 | 51 |
| Spironolactone | Spironolactone | 211 | 53 |
| Escitalopram Oxalate | Escitalopram Oxalate | 208 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 197 | 49 |
| Furosemide | Furosemide | 183 | 62 |
| Gabapentin | Gabapentin | 173 | 48 |
| Simvastatin | Simvastatin | 169 | 44 |
| Metformin Hcl Er | Metformin Hcl | 166 | 48 |
| Calcitriol | Calcitriol | 155 | 40 |
| Sertraline Hcl | Sertraline Hcl | 150 | 36 |
| Potassium Chloride | Potassium Chloride | 143 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 140 | 45 |
| Trazodone Hcl | Trazodone Hcl | 136 | 41 |
| Allopurinol | Allopurinol | 129 | 32 |
| Tramadol Hcl | Tramadol Hcl | 121 | 46 |
| Montelukast Sodium | Montelukast Sodium | 111 | 35 |
| Glipizide Er | Glipizide | 110 | 31 |
| Memantine Hcl | Memantine Hcl | 110 | 26 |
| Amoxicillin | Amoxicillin | 104 | 80 |
| Zolpidem Tartrate | Zolpidem Tartrate | 102 | 26 |
| Methylprednisolone | Methylprednisolone | 101 | 81 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 99 | 77 |
| Alendronate Sodium | Alendronate Sodium | 98 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 97 | 19 |
| Azithromycin | Azithromycin | 92 | 70 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 85 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 84 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 84 | 22 |
| Ozempic | Semaglutide | 84 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 83 | 25 |
| Metformin Hcl | Metformin Hcl | 78 | 28 |
| Bupropion Xl | Bupropion Hcl | 77 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 75 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 75 | 18 |
| Chlorthalidone | Chlorthalidone | 72 | 19 |
| Famotidine | Famotidine | 72 | 21 |
| Atenolol | Atenolol | 67 | 15 |
| Januvia | Sitagliptin Phosphate | 66 | 16 |
| Repatha Sureclick | Evolocumab | 66 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 65 | 44 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 64 | 57 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 64 | 19 |
| Carvedilol | Carvedilol | 63 | 21 |
| Ibandronate Sodium | Ibandronate Sodium | 62 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 60 | 26 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 60 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 57 | 16 |
| Warfarin Sodium | Warfarin Sodium | 56 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 55 | 21 |
| Synthroid | Levothyroxine Sodium | 53 | 14 |
| Mirtazapine | Mirtazapine | 52 | 19 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 48 | suppressed |
| Pregabalin | Pregabalin | 48 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | 11 |
| Meloxicam | Meloxicam | 45 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 43 | 11 |
| Estradiol | Estradiol | 42 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 41 | 12 |
| Meclizine Hcl | Meclizine Hcl | 41 | 22 |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 39 | 13 |
| Lansoprazole | Lansoprazole | 38 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 38 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 35 | 14 |
| Buspirone Hcl | Buspirone Hcl | 35 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 34 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 18 |
| Praluent Pen | Alirocumab | 33 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 32 | suppressed |
| Primidone | Primidone | 31 | suppressed |
| Verapamil Er | Verapamil Hcl | 31 | suppressed |
| Colchicine | Colchicine | 30 | suppressed |
| Rybelsus | Semaglutide | 30 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 30 | suppressed |
| Fluconazole | Fluconazole | 29 | 17 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 29 | 29 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 28 | 16 |
| Glipizide | Glipizide | 28 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 26 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Klor-Con M20 | Potassium Chloride | 26 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 25 | 18 |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Prednisone | Prednisone | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Verapamil Sr | Verapamil Hcl | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 18 | 18 |
| Cholestyramine | Cholestyramine (With Sugar) | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | 15 |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Premarin | Estrogens, Conjugated | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Trospium Chloride | Trospium Chloride | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $230.10 · 11 records | Amgen Inc. | ELIQUIS, JARDIANCE, OTEZLA, REPATHA, SHINGRIX, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error